Picture loading failed.

Anti-SELP therapeutic antibody (Pre-made Crizanlizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Crizanlizumab, sold under the brand name Adakveo, is a monoclonal antibody medication developed by Novartis targeted towards P-selectin. It was announced by the company as an effective drug to prevent vaso-occlusive crisis in patients with sickle cell anemia. The result of the Phase II SUSTAIN clinical trial was published in December 2016.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-123-1mg 1mg 3090
GMP-Bios-ab-123-10mg 10mg 21890
GMP-Bios-ab-123-100mg 100mg 148000
GMP-Bios-ab-123-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-SELP therapeutic antibody (Pre-made Crizanlizumab biosimilar,Whole mAb)
INN Name Crizanlizumab
TargetSELP
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesSelexys Pharmaceuticals;Novartis
Conditions ApprovedVaso-occlusive crisis
Conditions ActivePriapism;Myelofibrosis;COVID-19
Conditions Discontinuedna
Development Techna